A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy.

Document Type

Article

Publication Date

1-1-2021

Publication Title

Front Oncol

Keywords

oregon; portland; chiles

Abstract

Metaplastic breast cancer is a rare and often chemo-refractory subtype of breast cancer with poor prognosis and limited treatment options. Recent studies have reported overexpression of programmed death ligand 1 (PD-L1) in metaplastic breast cancers, and there are several reports of anti-PD-1/L1 being potentially active in this disease. In this case series, we present 5 patients with metastatic metaplastic breast cancer treated with anti-PD-1-based therapy at a single center, with 3 of 5 cases demonstrating a response to therapy, and one of the responding cases being a metaplastic lobular carcinoma with low-level hormone receptor expression. Cases were evaluated for PD-L1 expression, tumor infiltrating lymphocytes (TILs), DNA mutations, RNA sequencing, and T-cell receptor sequencing. Duration of the response in these cases was limited, in contrast to the more durable responses noted in other recently published reports.

Clinical Institute

Cancer

Clinical Institute

Women & Children

Department

Earle A. Chiles Research Institute

Department

Oncology

Department

Obstetrics & Gynecology

Link to Full Text

PSJH Full Text

Share

COinS